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Abstract
Background: Abundant evidence at the anatomical, electrophysiological, and molecular levels implicates metabotropic 
glutamate receptor subtype 5 (mGluR5) in addiction. Consistently, the effects of a wide range of doses of different mGluR5 
negative allosteric modulators (NAMs) have been tested in various animal models of addiction. Here, these studies were 
subjected to a systematic review to find out if mGluR5 NAMs have a therapeutic potential that can be translated to the 
clinic.
Methods: Literature on consumption/self-administration and reinstatement of drug seeking as outcomes of interest published 
up to April 2015 was retrieved via PubMed. The review focused on the effects of systemic (i.p., i.v., s.c.) administration of 
the mGluR5 NAMs 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) and 2-Methyl-6-(phenylethynyl)pyridine (MPEP) on 
paradigms with cocaine, ethanol, nicotine, and food in rats.
Results: MTEP and MPEP were found to reduce self-administration of cocaine, ethanol, and nicotine at doses ≥1 mg/kg and 
2.5 mg/kg, respectively. Dose-response relationship resembled a sigmoidal curve, with low doses not reaching statistical 
significance and high doses reliably inhibiting self-administration of drugs of abuse. Importantly, self-administration of 
cocaine, ethanol, and nicotine, but not food, was reduced by MTEP and MPEP in the dose range of 1 to 2 mg/kg and 2.5 
to 3.2mg/kg, respectively. This dose range corresponds to approximately 50% to 80% mGluR5 occupancy. Interestingly, the 
limited data found in mice and monkeys showed a similar therapeutic window.
Conclusion: Altogether, this review suggests a therapeutic window for mGluR5 NAMs that can be translated to the treatment 
of substance-related and addictive disorders.
Keywords: glutamate, mGluR5, addiction, MPEP, MTEP
Introduction
The significance of metabotropic glutamate receptor subtype 5 
(mGluR5) for psychiatry is predetermined by its distribution and 
function. In the brain, mGluR5 density (Shigemoto et al., 1993) 
peaks in structures involved in motor coordination (Conn et al., 
2005), reward-guided behavior (Russo and Nestler, 2013; Schultz, 
2015), and substance-related and addictive disorders (Everitt 
and Robbins, 2005; Volkow et  al., 2012). Furthermore, mGluR5 
is critically implicated in normal and aberrant neuroplasticity 
(Kalivas, 2009; Luscher and Huber, 2010; Kalivas and Volkow, 
2011) via structural and functional interactions with dopamine 
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D1, D2, NMDA, adenosine A2, and GABA receptors (Conn et al., 
2005; Bonsi et  al., 2008). Its pharmacological properties have 
been thoroughly described (Conn and Pin, 1997; Ferraguti and 
Shigemoto, 2006), and selective pharmacological agents target-
ing the mGluR5 have been developed (Gasparini et  al., 1999; 
Anderson et al., 2002). Preclinical research with these agents sug-
gests that this receptor is a candidate target for the treatment 
of MDD (Markou, 2007; Pilc et al., 2008; Palucha-Poniewiera et al., 
2013), Parkinson’s disease (Marino et  al., 2003; Johnson et  al., 
2009), schizophrenia (Conn et al., 2009; Herman et al., 2012), and 
addiction (Markou, 2007; Bird and Lawrence, 2009; Olive, 2009; 
Holmes et al., 2013; Pomierny-Chamiolo et al., 2014). The devel-
opment of highly selective mGluR5 radiotracers such as [11C]
ABP688 (Ametamey et  al., 2006, 2007) has enabled the in vivo 
assessment of mGluR5 via positron emission tomography (PET) 
in humans (Terbeck et al., 2015). ABP PET-studies demonstrated 
altered mGluR5 binding in subjects with MDD (Deschwanden 
et al., 2011) and to a lesser extent in OCD (Akkus et al., 2014). 
However, the largest alteration in mGluR5 binding so far was 
found in smoking addiction (Akkus et al., 2013). It was replicated 
(Hulka et al., 2014) and extended by evidence for normalization 
of mGluR5 binding after prolonged smoking cessation (Akkus 
et al., 2015). Reduced mGluR5 binding was also found in cocaine 
addicts (Milella et al., 2014) and to a lesser extent in occasional 
cocaine users (Hulka et  al., 2014), indicating a critical role for 
mGluR5 in human addiction and, consequently, in its treatment. 
Indeed, the introduction of selective and potent mGluR5 NAMs, 
such as 2-Methyl-6-(phenylethynyl)pyridine (MPEP) (Gasparini 
et al., 1999) and 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) 
(Anderson et al., 2002), has inspired a large and further growing 
number of experiments testing the effects of a wide dose range 
of different mGluR5 NAMs on various addiction models in mice, 
rats, and monkeys. From a clinical point of view, however, inno-
vation stemming from preclinical research needs to be system-
atically examined for its translational potential (Markou et al., 
2009). Here, we suggest 3 incremental requirements to be ful-
filled to demonstrate a therapeutic potential for mGluR5 NAMs 
in substance-related and addictive disorders, based on animal 
model-studies: (1) addiction-like animal behavior should be reli-
ably suppressed by mGluR5 NAMs; (2) moreover, there should be 
a clear-cut dose-response relationship allowing a prediction of 
which dose range and corresponding mGluR5 occupancy range 
is needed to reduce addiction-like behavior; and (3) finally, there 
should be a “therapeutic window” within which addiction-like 
animal behavior is suppressed without affecting responding 
to natural reinforcers. Previous reviews (Markou, 2007; Bird 
and Lawrence, 2009; Olive, 2009; Holmes et al., 2013; Pomierny-
Chamiolo et  al., 2014) have demonstrated the high efficacy of 
mGluR5 NAMs in reducing addiction-like behavior, as required 
by the first criterion. However, systematic reviews on the sec-
ond and third requirements are still missing. To this end, we 
examined the literature on the effects of mGluR5 NAMs on self-
administration of substances of abuse and food.
Methods
Literature was collected using PubMed (https://www.ncbi.
nlm.nih.gov/pubmed/) and the terms “mglur5” or “mglu5” fol-
lowed by “self-administration” and either “cocaine,” “nicotine,” 
“ethanol,” or “food.” For food, this search scope was extended 
by entering only “mglur5” or “mglu5” and “food” to account 
for studies in which animals had free access to food, without 
the need to perform an operant response. Only publications 
in English within the scope of PubMed until April 2015 were 
considered. Search results were narrowed down in 2 steps. First, 
only studies measuring consumption, self-administration, or 
reinstatement of food/drug seeking were included. In a second 
step, only reports on systemic, that is, i.p., s.c., or i.v. administra-
tion of mGluR5 NAMs were selected. Studies employing direct 
intracranial mGluR5 NAM administration to specific brain areas 
were excluded, since they cannot readily be translated to an 
established clinical administration routine and use an entirely 
different dose range.
In studies with direct access, animals could consume food or 
ethanol without the need to perform operant responses to gain 
access to it, and consumption was measured as the outcome 
of interest after administration of mGluR5 NAMs or placebo. In 
self-administration studies, animals were trained to perform 
operant responses (eg, lever pressing or nose poking) to gain 
access to the reinforcer, which was delivered in a receptacle or 
intravenously, through an implanted catheter. In reinstatement 
studies, self-administration training was followed by extinc-
tion and, subsequently, reinstatement of drug seeking by either 
a priming administration of the reinforcer (substance-induced 
reinstatement) or a response-contingent administration of the 
conditioned cues that had been delivered together with the 
reinforcer during self-administration training (cue-induced 
reinstatement). Thus, the main experimental paradigms were 
consumption under direct access to the reinforcer, self-adminis-
tration maintenance under a fixed reinforcement schedule, and 
substance- or cue-induced reinstatement of drug seeking.
A total of 125 reports (Chiamulera et al., 2001; Paterson et al., 
2003; Backstrom et al., 2004; Tessari et al., 2004; Bespalov et al., 
2005; Bradbury et al., 2005; Cowen et al., 2005; Kenny et al., 2005; 
Lee et al., 2005; McMillen et al., 2005; Olive et al., 2005; Paterson 
and Markou, 2005; Schroeder et  al., 2005; Varty et  al., 2005; 
Backstrom and Hyytia, 2006; Hodge et al., 2006; Iso et al., 2006; 
Lominac et al., 2006; Cowen et al., 2007; Liechti and Markou, 2007; 
Semenova and Markou, 2007; van der Kam et al., 2007; Adams 
et al., 2008; Besheer et al., 2008; Gupta et al., 2008; Osborne and 
Olive, 2008; Palmatier et  al., 2008; Platt et  al., 2008; Schroeder 
et  al., 2008; Gass et  al., 2009; Kumaresan et  al., 2009; Martin-
Fardon et al., 2009; Moussawi et al., 2009; Hao et al., 2010; Ploj 
et al., 2010; Sidhpura et al., 2010; Tronci et al., 2010; Eiler et al., 
2011; Popik et al., 2011; Tronci and Balfour, 2011; Martin-Fardon 
and Weiss, 2012; Varga et al., 2012; Keck et al., 2013; Watterson 
et al., 2013; Keck et al., 2014) on the effects of mGluR5 NAMs were 
extracted and classified with respect to the following param-
eters: publication (source of the report), mGluR5 NAM (MPEP, 
MTEP, fenobam, or MFZ 10–7), species (rats, mice, or monkeys), 
administration route (i.p., s.c., i.m., or i.v.), administered dose 
(mg/kg), and experimental paradigm (supplementary Figures 
1–4). Furthermore, the alpha error correction method reported 
was extracted for each study (supplementary Table 1). A focus on 
investigations administering MTEP or MPEP in rats was chosen, 
since the number of studies carried out in other species or with 
other mGluR5 NAMs was too low. To address criteria 1 and 2, 
as formulated above, 87 reports were extracted from 34 studies 
(supplementary Methods; supplementary Table  1). To address 
criterion 3, individual doses were aggregated in 3 dose ranges 
occupying <50%, 50% to 80%, or 80% to 100% of mGluR5. Dose 
ranges were chosen based on evidence that MTEP produces 50% 
to 80% mGluR5 occupancy when administered i.p. at 1.1 to 2 mg/
kg and 100% occupancy at doses of 3 mg/kg or more, while MPEP 
produces 50% to 80% mGluR5 occupancy at 2.3 to 3.2 mg/kg i.p. 
and 100% occupancy at doses of 10 mg/kg or higher (Anderson 
et al., 2003; Urban et al., 2003; Busse et al., 2004; Steckler et al., 
2005).
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Results
Robust evidence was found that both MTEP and MPEP sup-
press addiction-like behaviors for cocaine, ethanol, and nicotine 
(criterion 1)  across various experimental models of addiction 
(Figures 1 and 2, A-C). In 47 of 52 reports (90%), a significant 
inhibiting effect of at least one of the administered mGluR5 
NAM doses on addiction-like behavior in rats was found. This 
cannot be explained by “false positives” due to alpha error infla-
tion caused by multiple comparisons for 2 reasons. First, statis-
tical correction for multiple comparisons was applied in 30 of 
34 studies (88%) (supplementary Table 1). Second, not a single 
report of statistically enhanced addiction-like behavior by treat-
ment with any NAM dose was found. The graphical summary 
of these effects revealed a sigmoidal dose response-relationship 
(criterion 2): for each individual report there was a threshold 
below which the effect of no tested mGluR5 NAM dose reached 
statistical significance, whereas for all doses above this thresh-
old, significant effects were observed. There was only one 
exception, where 1 and 10 but not 3 mg/kg MPEP i.p. inhibited 
cue-induced reinstatement of ethanol seeking in rats (Schroeder 
et  al., 2008) (Figure  2B). Notably, the authors pointed out that 
this finding was due to a single outlier in the 3-mg/kg treatment 
group (Schroeder et  al., 2008). To explore this dose-response 
relationship with regard to receptor occupancy levels, all reports 
on cocaine, ethanol, and nicotine were pooled together in one 
larger group, substances of abuse, and individual doses were 
grouped in dose ranges according to mGluR5 occupancy levels 
(Figure 3). Only 21% of MTEP and 15% of MPEP doses producing 
<50% mGluR5 occupancy significantly inhibited addiction-like 
behavior (Figure 3A-B). In the dose range producing 50% to 80% 
mGluR5 occupancy, 71% of MTEP doses and 57% of MPEP doses 
significantly attenuated addiction-like behavior. This percent-
age grew further, reaching 84% for MTEP and 88% for MPEP in the 
dose range producing 80% to 100% mGluR5 occupancy. This dose-
response relationship was similar yet not identical for different 
substances of abuse (supplementary Figures 5 and 6). MTEP in 
the dose range 1 to 2 mg/kg inhibited addiction-like behavior for 
cocaine and ethanol for 60% and 88% of doses, respectively (sup-
plementary Figure 5). While 80% of MPEP doses in the range 2.5 
to 3.2 mg/kg significantly inhibited addiction-like behavior for 
cocaine, 71% reduced addiction-like behavior in ethanol para-
digms and 36% in nicotine paradigms (supplementary Figure 6). 
Figure 1. The effects of 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) on consumption, self-administration, and reinstatement of seeking of cocaine (A), ethanol 
(B), nicotine (C), and food (D). Left Y-axis labels indicate study citation and administration route. Right Y-axis labels indicate the experimental paradigm. X-Axis labels 
indicate the MTEP doses administered in mg/kg body weight. Blue squares indicate a significant reduction of the outcome measure and grey squares indicate non-
significant effects, as reported by the authors. Empty (white) squares indicate that the respective dose has not been tested. Abbreviations: Abs-ind reinst, abstinence-
induced reinstatement; Break point, analysis of break point under progressive reinforcement schedule; Cont cue-ind reinst, context- and cue-induced reinstatement; 
Cue- and s-ind reins, simultaneous cue- and substance priming-induced reinstatement; Cue-ind reinst, cue-induced reinstatement of food/drug seeking; D-r curve, 
dose-response curve; direct access, direct access to food/drug, with no operant responding needed; Schedule-ind reinst, schedule-induced reinstatement of food/
drug seeking; seeking replacement, reinstatement by operant-response noncontingent experimenter-delivered reinforcers; self-admin maint, maintenance of food/
drug self-administration; S-ind reinst, substance-induced reinstatement of food/drug seeking; Stress-ind reinst, stress-induced reinstatement of food/drug seeking.
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Figure 3. Dose dependency of the effects of 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) in experimental paradigms employing cocaine, ethanol, or nicotine (A) as 
well as in food paradigms (C). Dose dependency of the effects of 2-Methyl-6-(phenylethynyl)pyridine (MPEP) in experimental paradigms employing cocaine, ethanol, 
and nicotine (B) as well as in food paradigms (D). Dose ranges have been chosen to reflect <50% mGluR5 occupancy (<1 mg/kg MTEP, <2.5 mg/kg MPEP), 50% to 80% 
mGluR5 occupancy (1–2 mg/kg MTEP, 2.5–3.2 mg/kg MPEP), and up to 100% mGluR5 occupancy (>2 mg/kg MTEP or >3.2 mg/kg MPEP).
Figure 2. Effects of 2-Methyl-6-(phenylethynyl)pyridine (MPEP) on experimental paradigms employing cocaine (A), ethanol (B), nicotine (C), and food (D) as reinforcers. 
Color coding as in Figure 1.
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Apparently, the effectiveness threshold for MPEP in nicotine 
paradigms is higher, around 5 mg/kg (Figure 2C).
Strikingly, both MTEP and MPEP showed much weaker effects 
in experimental paradigms employing food as a reinforcer 
(Figure  3C-D): significant effects for any of the mGluR5 NAM 
dose tested were found in 9 of 19 reports for MTEP (47%) and 3 of 
16 reports for MPEP (19%) (Figures 1D and 2D). When taking the 
dose response-relationship into account, MTEP reliably inhib-
ited food intake only at 10 mg/kg mGluR5. When considering 
only the dose range producing 50% to 80% receptor occupancy 
(1–2 mg/kg MTEP and 2.5–3.2 mg/kg MPEP), significant effects 
were found in 2 of 10 reports for MTEP and 1 of 12 reports for 
MPEP. In sum, MTEP and MPEP inhibit addiction-like behavior 
for cocaine, ethanol, and nicotine across different experimen-
tal paradigms without impairing food self-administration and 
consumption at doses producing 50% to 80% mGluR5 occupancy 
(criterion 3). Does this general finding hold when restricted to 
one outcome of interest? Analysis of reports on the effective 
doses of MTEP (1 mg/kg or more) and MPEP (2.5 mg/kg or more) 
showed that maintenance of self-administration was meas-
ured by far most frequently (supplementary Figures 7 and 8). 
Therefore, further analysis focused on this outcome of interest. 
The dose range 1 to 2 mg/kg MTEP significantly reduced self-
administration maintenance in 5 of 9 cases (56%) for substances 
of abuse (0/2 cocaine, 4/5 ethanol, 1/2 nicotine) and 1 of the 5 
cases (20%) for food (Figure 1). The dose range 2.5 to 3.2 mg/kg 
MPEP significantly reduced this outcome in 7 of 9 cases (78%) for 
substances of abuse (2/2 cocaine, 1/1 ethanol, 4/6 nicotine) and 
in none of 7 cases (0%) for food (Figure 2D). Taken together, 1 to 
2 mg/kg MTEP and 2.5 to 3.2 mg/kg MPEP significantly inhibited 
self-administration maintenance for drugs of abuse in 12 of 18 
cases (67%) and 1 of 12 (8%) cases for food self-administration 
(criterion 3). These effects are not altered by food restriction, 
which can increase glutamate receptor-mediated dopamine 
activity and is widely used in experimental protocols to enhance 
operant responding for drugs of abuse or food (Pothos et al., 1995; 
Avena et al., 2008; Branch et al., 2013). mGluR5 NAMs inhibited 
maintenance of self-administration of cocaine, nicotine, or alco-
hol in 5 of 8 reports (63%) in which access to food was restricted 
(Paterson et al., 2003; Liechti and Markou, 2007; Palmatier et al., 
2008; Tronci et  al., 2010; Tronci and Balfour, 2011). Similarly, 
mGluR5 NAMs reduced self-administration maintenance for 
cocaine, nicotine, or alcohol in 7 of 10 reports (70%) in which 
animals had ad libitum access to food (Cowen et al., 2005; Kenny 
et  al., 2005; Schroeder et  al., 2005; Martin-Fardon et  al., 2009; 
Sidhpura et  al., 2010; Keck et  al., 2014). Furthermore, mGluR5 
NAMs did not impact self-administration of food, regardless of 
whether access to food was restricted or not (Figures 1D and 
2D; supplementary Table 2). Based on these reports, we conclude 
that criterion 3 regarding the “therapeutic window” is met for 
maintenance of self-administration in rats.
Importantly, the limited evidence from studies in mice 
and monkeys supports the findings in rats (Figures 4 and 5). 
In mice, doses of 10 and 20 mg/kg MPEP reduced self-adminis-
tration and consumption of ethanol without a reliable impact 
on self-administration and consumption of food (Figure  4B). 
Interestingly, this therapeutic range begins at 10 mg/kg, which 
produces 50% mGluR5 occupancy over 1 hour in mice and thus 
closely corresponds to the therapeutic dose range identified for 
MTEP and MPEP in rats (Anderson et al., 2003). Reports on the 
effects of MTEP on ethanol self-administration are less consist-
ent but also limited in number, which warrants caution in their 
interpretation (Figure  4A). In monkeys, limited evidence sug-
gests that 0.3 mg/kg MPEP i.m. suppress self-administration of 
cocaine but not food (Figure 5). Although these results have to be 
interpreted with caution due to the low number of reports avail-
able (supplementary Methods), they also suggest a therapeutic 
dose range for MPEP.
Finally, reports on the action of mGluR5 NAMs on metham-
phetamine and opiates is scarce and insufficient to draw firm 
conclusions. In rats, methamphetamine self-administration 
maintenance was reduced by i.p.  1 and 3 mg/kg, but not by 
Figure 4. Effects of 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) (A) and 2-Methyl-6-(phenylethynyl)pyridine (MPEP) (B) on self-administration and consumption of 
ethanol and food in mice. Color coding and axis labelling as in Figures 1 and 2. The red square indicates increased food intake after MPEP administration.
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0.3 mg/kg MTEP (Osborne and Olive, 2008). Another metham-
phetamine study in rats showed reduction of both substance-
induced and cue-induced methamphetamine seeking by i.p. 1 
and 3 mg/kg, but not by 0.3 mg/kg MTEP, while breaking point 
and self-administration maintenance were reduced by 3 mg/kg, 
but not by 0.3 and 1 mg/kg and MTEP (Gass et al., 2009). These 
results follow the same sigmoidal dose-response relationship 
and suggest that mGluR5 NAMs might reduce addiction-like 
behavior for methamphetamine in the therapeutic window 
outlined above. In mice, self-administration maintenance and 
cue-induced seeking for morphine were inhibited by a single 
i.p. dose of 20 mg/kg MTEP (Brown et al., 2012). In rats, heroine 
self-administration maintenance was inhibited by i.p.  20 but 
not 1.25, 2.5, 5, or 10 mg/kg MPEP (van der Kam et al., 2007). The 
last report suggests that generally higher mGluR5 doses might 
be needed to suppress heroin self-administration but should be 
interpreted with caution until corroborated and extended by 
further studies.
Conclusions
This is the first systematic review to show that MTEP and MPEP 
reduce self-administration of cocaine, ethanol, and nicotine (cri-
terion 1) at doses producing 50% to 80% mGluR5 occupancy (cri-
terion 2) without impairing food self-administration (criterion 3). 
These results indicate a therapeutic potential for mGluR5 NAMs 
in the treatment of substance-related and addictive disorders.
Aggregating heterogeneous outcome measures, proverbi-
ally referred to as “comparing apples with oranges,” is a major 
methodological issue in systematic reviews (Leucht et al., 2009). 
Indeed, different experimental paradigms, such as cue-induced 
reinstatement of drug seeking and maintenance of drug self-
administration, can reflect different aspects of substance abuse 
disorders (Robinson, 2004; Koob et al., 2009) that warrant caution 
when making general statements about the effects of mGluR5 
NAMs on addiction behavior. However, within the wide spec-
trum of the outcome measures reviewed here, evidence for the 
effects of mGluR5 NAMs on the maintenance of self-administra-
tion still holds when restricted to studies on self-administration 
of food or drugs of abuse. Self-administration paradigms are 
considered a model of binge-intoxication in human substance-
related and addictive disorders (Koob et  al., 2009) with high 
etiological and construct validity (Markou et al., 2009; O’Connor 
et al., 2011; Robbins, 2012). Furthermore, self-administration is 
a key behavioral element of substance abuse and addictive dis-
orders (American Psychiatric et al., 2013). Therefore, the effects 
of mGluR5 NAMs on self-administration paradigms indicate a 
significant clinical impact if translated to the treatment of sub-
stance-related and addictive disorders.
The literature reviewed here clearly shows that MTEP 
reduces self-administration of cocaine, ethanol, and nico-
tine at lower doses (1–2 mg/kg) than MPEP (2.5–3.2 mg/kg). This 
finding is consistent with the higher mGluR5 occupancy rates 
produced by MTEP when administered at equal doses as MPEP 
(Anderson et al., 2003; Busse et al., 2004). A therapeutic window 
for MTEP and MPEP was identified at doses reported to produce 
approximately 50% to 80% mGluR5 occupancy (Anderson et al., 
2003; Urban et al., 2003; Busse et al., 2004; Steckler et al., 2005), 
although a more recent investigation employing a different 
assessment method suggested lower and almost identical ED50 
Figure 5. Effects of 2-Methyl-6-(phenylethynyl)pyridine (MPEP) on cocaine and food paradigms in monkeys. Color coding and axis labelling as in Figures 1 and 2.
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for these substances (Nagel et  al., 2015). It is hard to identify 
the exact mGluR5 occupancy rate for an optimal ratio of reduc-
tion in substance of abuse self-administration to impairment in 
food consumption. However, the literature reviewed here sug-
gests this occupancy rate is in the range 50% to 80%, as report-
edly produced by i.p. administrations of 1 to 2 mg/kg MTEP or 2.5 
to 3.2 mg/kg MPEP. Food consumption can be inhibited by MTEP 
but only when administered at doses more than 3 times higher 
than needed to block 100% mGluR5 for 1 hour (Anderson et al., 
2003). Interestingly, MPEP can also inhibit food self-administra-
tion when administered at comparably high doses, that is, 10 to 
30 mg/kg (Varty et al., 2005). It is important to point out that the 
dose ranges required for robust impact on food self-administra-
tion lie well outside of the therapeutic window and are likely 
irrelevant for the translation of mGluR5 NAMs to the treatment 
of substance-related and addictive disorders.
Self-administration of cocaine, ethanol, and nicotine, which 
greatly differ with respect to their pharmacodynamics, was 
reduced by similar levels of mGluR5 negative allosteric modula-
tion. This finding indicates that mGluR5 NAMs act on a molecu-
lar final common pathway affected by these substances of abuse 
(Everitt and Robbins, 2005; Nestler, 2005; Koob and Volkow, 2010) 
rather than at their primary binding sites. According to the 
glutamate homeostasis hypothesis (Kalivas, 2009; Kalivas and 
Volkow, 2011), synaptic glutamate overflow activating mGluR5 
drives together with reduced function of mGluR2/3 and gluta-
mate/cysteine transporter pathological neuroplastic changes 
in the ventral striatum in addiction. The reduction in mGluR5 
binding observed in human addiction (Akkus et al., 2013, 2015; 
Hulka et al., 2014; Martinez et al., 2014; Milella et al., 2014) can be 
thought of as a compensatory reaction (Kalivas, 2009).
This review focused on MTEP and MPEP because of the scarce 
literature on other mGluR5 NAMs. Both substances, however, 
have off-target effects that hinder their clinical application. 
MPEP is a competitive NMDA antagonist (O’Leary et  al., 2000; 
Movsesyan et al., 2001), which may cause potentially severe side 
effects, such as hallucinations. Both MTEP and MPEP act as com-
petitive inhibitors of the hepatic enzyme CYP1A2 and can cause 
clinically important interactions with substances metabolized 
by this enzyme, such as theophylline, caffeine, fluvoxamine, and 
olanzapine (Green et al., 2004). Both MTEP and MPEP are rapidly 
metabolized after administration (Keck et al., 2013). Other highly 
potent and selective mGluR5 NAMs, such as fenobam (Pecknold 
et al., 1982; Porter et al., 2005; Berry-Kravis et al., 2009), mavo-
glurant (Kumar et al., 2013; Stocchi et al., 2013; Reilmann et al., 
2015), ADX10059, AZD2066 (Keywood et  al., 2009; Zerbib et  al., 
2010, 2011; Rohof et al., 2012), and AZD9272 (Kalliomaki et al., 
2013), have been investigated in humans for different indica-
tions and could find application in the treatment of addiction if 
their pharmacokinetics and side effect profiles prove favorable. 
Moreover, the industry continuously develops new compounds 
(Felts et al., 2009; Emmitte, 2011; Kaae et al., 2012; Keck et al., 
2012; Molck et al., 2012, 2014; Anighoro et al., 2015; Jaeschke et al., 
2015; Lindemann et al., 2015) and new mGluR5-specific PET trac-
ers (Yu, 2007; Mu et al., 2010; Sobrio, 2013), such as [18F]PSS232 
(Sephton et  al., 2015) and [18F]FPEB (Lim et  al., 2014). These 
developments will inspire new preclinical and clinical research, 
which can build on the findings reported here by focusing on 
dose / receptor occupancy ranges that could more directly be 
translated to the clinic (Markou et al., 2009). On the one hand, 
different behavioral outcomes with incremental construct 
validity should be employed to investigate the action of mGluR5 
on different aspects of human pathology (Koob et al., 2009). On 
the other hand, pharmacological small animal PET studies are 
needed to show the longitudinal impact of substances of abuse 
and their pharmacological treatment on mGluR5.
Furthermore, clinical studies with mGluR5 NAMs conducted 
in accordance with the National Institute of Mental Health 
Research Domain Criteria (Insel et al., 2010, 2014) should con-
sider cutting across disorders characterized by action-to-habit 
devolution (Fineberg et al., 2010; Robbins, 2012). These include 
substance abuse disorders (Everitt and Robbins, 2005) but also 
binge eating disorder (Smith and Robbins, 2013), bulimia ner-
vosa (Calero-Elvira et al., 2009), and pathological gambling (Petry, 
2006; Potenza, 2006; Leeman and Potenza, 2012). PET studies are 
needed to investigate the role for mGluR5 in these disorders 
(Akkus et al., 2013, 2014, 2015; Hulka et al., 2014; Milella et al., 
2014), while clinical trials are needed to probe the therapeu-
tic potential of mGluR5 agents. The results of this systematic 
review corroborate the feasibility of such pharmacological treat-
ment by showing a therapeutic window for mGluR5 NAMs and 
suggest that research in this field should be further stimulated.
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